Prime Medicine (PRME) Cash & Equivalents (2021 - 2026)

Prime Medicine (PRME) has 6 years of Cash & Equivalents data on file, last reported at $64.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 30.23% year-over-year to $64.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.1 million (down 30.23% YoY) and the FY2025 annual result came in at $63.0 million, down 65.46% from the prior year.
• Cash & Equivalents rose to $64.1 million in Q1 2026, from $63.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $187.6 million in Q4 2022 to a low of $41.6 million in Q4 2023.
• A 5-year average of $95.7 million and a median of $91.9 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 77.84% — and 2024, when it jumped 338.92%.
• Tracing PRME's Cash & Equivalents over 5 years: stood at $187.6 million in 2022, then sank by 77.84% to $41.6 million in 2023, then surged by 338.92% to $182.5 million in 2024, then sank by 65.46% to $63.0 million in 2025, then gained by 1.7% to $64.1 million in 2026.
• The last three Cash & Equivalents figures came in at $64.1 million (Q1 2026), $63.0 million (Q4 2025), and $71.4 million (Q3 2025), per Business Quant data.